Partagez sur FacebookPartagez sur TwitterEnvoyer par courriel

33- Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.

JAMA Neurol. 2024 Apr 29:e240991. doi: 10.1001/jamaneurol.2024.0991.